Late risk-on move after the Wall St.....>

MARKET TALK: Late risk-on move after the Wall St. bell was noted on Thursday,

centring on an article released by STAT, which describes itself as "reporting

from the frontiers of health and medicine."

- The article noted that "a Chicago hospital treating severe Covid-19 patients

with Gilead Sciences' antiviral medicine remdesivir in a closely watched

clinical trial is seeing rapid recoveries in fever and respiratory symptoms,

with nearly all patients discharged in less than a week, STAT has learned.

Remdesivir was one of the first medicines identified as having the potential to

impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests. The

entire world has been waiting for results from Gilead's clinical trials, and

positive results would likely lead to fast approvals by the Food and Drug

Administration and other regulatory agencies. If safe and effective, it could

become the first approved treatment against the disease."